STOCK TITAN

Vanguard Capital Management (NYSE: CVS) reports 95.6M shares, 7.51% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Vanguard Capital Management reports beneficial ownership of 95,598,528 shares of CVS Health Corp common stock, representing 7.51% of the class as of 03/31/2026. The filing states sole voting power of 12,948,452 shares and sole dispositive power of 95,598,528 shares. The filing lists Vanguard Capital Management's address in Malvern, PA, and notes that the holdings include shares managed across Vanguard funds and client accounts. The filing is signed by Ashley Grim as Head of Global Fund Administration on 04/29/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard holds a sizeable passive stake in CVS at 7.51% as of 03/31/2026.

Vanguard Capital Management reports 7.51% beneficial ownership of CVS common stock, totaling 95,598,528 shares. The filing attributes voting and dispositive powers across Vanguard business units and funds rather than to a single proprietary account.

Holder decisions and fund-level rebalancing will determine future activity; subsequent filings will show any material changes in percent ownership.

Voting vs dispositive power is concentrated: limited voting, broad dispositive control.

The filing shows sole voting power of 12,948,452 shares and sole dispositive power of 95,598,528 shares. This pattern is typical for large asset managers where voting authority may be segmented across affiliates.

Significant passive stakes above 5% trigger public disclosure obligations and can matter for proxy season dynamics; timing of any engagement is not provided.

Beneficial ownership 95,598,528 shares as of 03/31/2026
Percent of class 7.51% percentage of CVS common stock
Sole voting power 12,948,452 shares shares with sole power to vote
Sole dispositive power 95,598,528 shares shares with sole power to dispose
Beneficial ownership regulatory
"Amount beneficially owned: 95598528"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 95598528"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G regulatory
"Item 1. (a) Name of issuer: CVS Health Corp"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





126650100

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026

FAQ

How many CVS shares does Vanguard Capital Management report owning?

Vanguard reports beneficial ownership of 95,598,528 shares of CVS common stock as of 03/31/2026. The filing lists this stake as 7.51% of the class and discloses voting and dispositive powers.

What voting power does Vanguard report for CVS (CVS)?

The filing states Vanguard has sole voting power over 12,948,452 shares and sole dispositive power over 95,598,528 shares. Shared voting and dispositive powers are reported as zero.

Does Vanguard hold CVS shares on behalf of other Vanguard funds or clients?

Yes. The filing explains the holdings include securities held by Vanguard funds and client accounts over which Vanguard affiliates exercise dispositive and/or voting power, as described in the disclosure paragraph.

What percent of CVS is owned by Vanguard according to this filing?

Vanguard reports ownership equal to 7.51% of CVS common stock as of 03/31/2026. The filing characterizes this as beneficial ownership across Vanguard-managed vehicles.

Who signed the Schedule 13G for Vanguard and when?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with signature date 04/29/2026, certifying the reported ownership.